| May 2012 | ||||||
|---|---|---|---|---|---|---|
| S | M | T | W | T | F | S |
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | ||
From the New York Times:
The biotechnology company Celgene said yesterday that its cancer drug Revlimid had performed better than expected in two clinical trials, proving so effective that the studies were being stopped early so that all patients could be offered the drug.
...In the two trials, involving 705 patients with multiple myeloma, a blood cancer, the combination of Revlimid and a steroid delayed the worsening of the disease compared with a placebo and the steroid. The difference was so great that the committee overseeing patient safety decided to stop the trials. The company said the data from the trials would be released at medical conferences this spring.
Celgene’s president and chief operating officer, Sol J. Barer, said the early conclusion to the trials would allow the company to seek approval to treat multiple myeloma a few months sooner than it had planned. “It’s one of the seminal events in the life of a company,” Dr. Barer said.
I’m not sure I would have taken this report seriously if I’d seen it in a substantially lesser publication. It’s interesting how reliable the NY Times is, and what a great resource it is, when politics are not involved.
